Table 3 Laboratory findings
Findings | All participants (N = 165) | COVID-19 present/overcome (n = 13) | COVID-19 absent (n = 152) | P value |
|---|---|---|---|---|
Leucocyte count, × 109 per L | 11.5 ± 9.4 | 12.9 ± 9.5 | 11.4 ± 9.4 | .77 |
< 10 | 82 (49.7) | 6 (46.2) | 76 (50.0) | .79 |
≥ 10 | 83 (50.3) | 7 (53.8) | 76 (50.0) | |
Lymphocyte count, × 109 per L, (n = 90) | 1.2 ± 0.7 | 1.5 ± 0.9 | 1.2 ± 0.6 | .31 |
< 1.0 | 41/90 (45.6) | 4/9 (44.4) | 37/81 (45.7) | .94 |
≥ 1.0 | 49/90 (54.4) | 5/9 (55.6) | 44/81 (54.3) | |
C-reactive protein, mg/L, (n = 164) | 68.9 ± 74.0 | 95.1 ± 88.2 | 66.6 ± 72.6 | .34 |
Procalcitonin, ng/mL, (n = 93) | 1.6 ± 4.6 | 0.6 ± 0.8 | 1.7 ± 4.8 | .99 |
≥ 0.5 | 29/93 (31.2) | 3/7 (42.9) | 26/86 (30.2) | .67 |
IL-6, pg/mL, (n = 33) | 154.7 ± 255.2 | 29.4 ± 20.8 | 177.9 ± 272.9 | .34 |
d-dimers, mg/L, (n = 63) | 1.0 ± 1.4 | 0.5 ± 3.6 | 1.1 ± 1.5 | .74 |
> 0.5 | 29/60 (48.3) | 2/5 (40.0) | 27/55 (40.1) | > .99 |
Fibrinogen, g/L, (n = 72) | 4.2 ± 1.7 | 4.6 ± 1.5 | 4.2 ± 1.7 | .26 |
> 5.0 | 22/72 (30.6) | 5/8 (62.5) | 17/64 (26.6) | .051 |
Hemoglobin, g/L | 119.7 ± 244.0 | 125. 1 ± 244.0 | 119.2 ± 249.0 | .38 |
High-sensitive cardiac troponin I, pg/mL | ||||
Male (n = 53) | 79.8 ± 221.0 | 11.0 ± 7.6 | 98.7 ± 196.8 | .78 |
Female (n = 39) | 90.5 ± 188.9 | 42.9 ± 51.1 | 81.8 ± 226.8 | .25 |
> 34 (male), > 16 (female) | 35/92 (38.0) | 1/7 (14.3) | 34/85 (40.0) | .25 |
NT-proBNP, ≥ 500 pg/mL, (n = 55) | 18/55 (34.6) | 2/3 (66.7) | 16/52 (30.8) | .25 |
Serum Ferritin, μg/L, (n = 57) | 768.0 ± 1253.9 | 705.4 ± 581.4 | 775.3 ± 1314.0 | .25 |
> 300 | 26/56 (46.4) | 4/6 (66.7) | 22/50 (44.0) | .29 |
Creatinine, μmol/L, (n = 160) | 122.3 ± 90.7 | 116.3 ± 47.9 | 122.8 ± 93.7 | .40 |
> 150 (male), > 124 (female) | 32/159 (20.1) | 3/13 (23.1) | 29/146 (19.9) | .73 |